Biocon Profit Triples As ‘Very Attractive’ Biosimilar Opportunities Eyed
This article was originally published in PharmAsia News
Biocon, India’s biggest biotechnology firm, says its quarterly net profit tripled from a year ago, driven by a one-off IPO gain, and that it is on track to make regulatory filings for several biosimilars in the US and European markets during the next fiscal year.
You may also be interested in...
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.